Clinical trial · Interventional
Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus
Monocentric Open Label Phase I Immunotherapy Trial of Breast Cancer Patients With a Non-replicating Recombinant Vaccinia Virus Expressing Cancer/Testis Antigens and Cluster of Differentiation Antigen 80 (CD80)-CD40L Costimulatory Molecules.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): not sufficiently staff available to perform trial
Summary
Brief summary (as posted)
Monocentric open-label phase I/II trial aiming at evaluating, in adjuvant setting, safety (primary outcome), immunological and clinical efficacy (secondary outcomes) of a non replicating recombinant vaccinia virus expressing cancer/testis antigen (CTA) derived epitopes and CD80 and CD40 ligand (CD40L, CD154) costimulatory molecules in patients with CTA expressing tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Carcinoma | Breast Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| rVV-740CTA | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- rVV-740CTA vaccine
- interventionNames
- Biological: rVV-740CTA
Primary outcomes (2)
- measure
- number of adverse Events
- timeFrame
- 2 years
- description
- Safety measured by assessment of number of adverse events that have occured
- measure
- number of serious adverse Events
- timeFrame
- 2 years
- description
- Safety measured by assessment of number of serious adverse Events that have occured
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Surgically treated M0 patients with solid tumors * Tumor expressing at least one of the vaccine targeted antigens Melanoma-associated antigen (MAGE)-A1, -A2, * A3, -A4, -A6, -A10, -A12 or New York (NY) esophageal squamous cell carcinoma-1 (ESO-1) (NY-ESO-1) (by real-time quantitative PCR (RT-qPCR)) * Patient expressing the targeted Human Leukocyte Antigen (HLA) restriction (A0201 /A0101/ B3501) * 4 weeks interval following surgical resection of tumor and, if applicable, completion of adjuvant therapy. * Karnofsky over 70% * No other concomitant malignancy Exclusion Criteria: * History of anaphylaxis or severe allergic reaction * Severe heart, lung, kidney, liver or psychiatric condition * Concurrent immunosuppressive therapy or impaired immune system
References
Publications (0)
Data not yet available